Maria S. Jiao

Maria S. Jiao

Auto-generated profile, based on publicly available information

Maria S. Jiao

Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
NBNir Ben-Chetrit
Nir Ben-Chetrit
XNXiang Niu
Xiang Niu
ASAriel D. Swett
Ariel D. Swett
JSJesus Sotelo
Jesus Sotelo
MJMaria S. Jiao
Maria S. Jiao
DLDan A. Landau
Dan A. Landau

13 December 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SSSai Kiran Sharma
Sai Kiran Sharma
KMKyeara N. Mack
Kyeara N. Mack
APAlessandra Piersigilli
Alessandra Piersigilli
JPJacob Pourat
Jacob Pourat
KEKimberly J. Edwards
Kimberly J. Edwards
BZBrian Zeglis
Brian Zeglis
Purpose: Advances in our understanding of the contribution of aberrant glycosylation to the pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development of mucin-targeted therapies. Here, we validate the tumor-targeting ability of a novel monoclonal antibody (mAb), AR9.6, that binds MUC16 and abrogates downstream oncogenic signaling to confer a therapeutic response. Experimental Design: The in vitro and ex vivo validation of the binding of AR9.6 to MUC16 was achieved via flow cytometry, radioligand binding assay (RBA), and immunohistochemistry (IHC). The in vivo MUC16 targeting of AR9.6 was validated by creating a 89Zr-labeled radioimmunoconjugate of the mAb and utilizing immunoPET and ex vivo biodistribution studies in xenograft models of human ovarian and pancreatic cancer. Results: Flow cytometry, RBA, and IHC revealed that AR9.6 binds to ovarian and pancreatic cancer cells in an MUC16-dependent manner. The in vivo radiopharmacologic profile of 89Zr-labeled AR9.6 in mice bearing ovarian and pancreatic cancer xenografts confirmed the MUC16-dependent tumor targeting by the radioimmunoconjugate. Radioactivity uptake was also observed in the distant lymph nodes (LNs) of mice bearing xenografts with high levels of MUC16 expression (i.e., OVCAR3 and Capan-2). IHC analyses of these PET-positive LNs highlighted the presence of shed antigen as well as necrotic, phagocytized, and actively infiltrating neoplastic cells. The humanization of AR9.6 did not compromise its ability to target MUC16-expressing tumors. Conclusions: The unique therapeutic mechanism of AR9.6 combined with its excellent in vivo tumor targeting makes it a highly promising theranostic agent. huAR9.6 is poised for clinical translation to impact the management of metastatic ovarian and pancreatic cancers.

31 March 2023
Verified
Other
Open access
SSSai Kiran Sharma
Sai Kiran Sharma
KMKyeara N. Mack
Kyeara N. Mack
APAlessandra Piersigilli
Alessandra Piersigilli
JPJacob Pourat
Jacob Pourat
KEKimberly J. Edwards
Kimberly J. Edwards
BZBrian Zeglis
Brian Zeglis
Purpose:Advances in our understanding of the contribution of aberrant glycosylation to the pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development of mucin-targeted therapies. Here, we validate the tumor-targeting ability of a novel monoclonal antibody (mAb), AR9.6, that binds MUC16 and abrogates downstream oncogenic signaling to confer a therapeutic response.Experimental Design:The in vitro and ex vivo validation of the binding of AR9.6 to MUC16 was achieved via flow cytometry, radioligand binding assay (RBA), and immunohistochemistry (IHC). The in vivo MUC16 targeting of AR9.6 was validated by creating a 89Zr-labeled radioimmunoconjugate of the mAb and utilizing immunoPET and ex vivo biodistribution studies in xenograft models of human ovarian and pancreatic cancer.Results:Flow cytometry, RBA, and IHC revealed that AR9.6 binds to ovarian and pancreatic cancer cells in an MUC16-dependent manner. The in vivo radiopharmacologic profile of 89Zr-labeled AR9.6 in mice bearing ovarian and pancreatic cancer xenografts confirmed the MUC16-dependent tumor targeting by the radioimmunoconjugate. Radioactivity uptake was also observed in the distant lymph nodes (LNs) of mice bearing xenografts with high levels of MUC16 expression (i.e., OVCAR3 and Capan-2). IHC analyses of these PET-positive LNs highlighted the presence of shed antigen as well as necrotic, phagocytized, and actively infiltrating neoplastic cells. The humanization of AR9.6 did not compromise its ability to target MUC16-expressing tumors.Conclusions:The unique therapeutic mechanism of AR9.6 combined with its excellent in vivo tumor targeting makes it a highly promising theranostic agent. huAR9.6 is poised for clinical translation to impact the management of metastatic ovarian and pancreatic cancers.

31 March 2023
Verified
Other
Open access
SSSai Kiran Sharma
Sai Kiran Sharma
KMKyeara N. Mack
Kyeara N. Mack
APAlessandra Piersigilli
Alessandra Piersigilli
JPJacob Pourat
Jacob Pourat
KEKimberly J. Edwards
Kimberly J. Edwards
BZBrian Zeglis
Brian Zeglis
Purpose:Advances in our understanding of the contribution of aberrant glycosylation to the pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development of mucin-targeted therapies. Here, we validate the tumor-targeting ability of a novel monoclonal antibody (mAb), AR9.6, that binds MUC16 and abrogates downstream oncogenic signaling to confer a therapeutic response.Experimental Design:The in vitro and ex vivo validation of the binding of AR9.6 to MUC16 was achieved via flow cytometry, radioligand binding assay (RBA), and immunohistochemistry (IHC). The in vivo MUC16 targeting of AR9.6 was validated by creating a 89Zr-labeled radioimmunoconjugate of the mAb and utilizing immunoPET and ex vivo biodistribution studies in xenograft models of human ovarian and pancreatic cancer.Results:Flow cytometry, RBA, and IHC revealed that AR9.6 binds to ovarian and pancreatic cancer cells in an MUC16-dependent manner. The in vivo radiopharmacologic profile of 89Zr-labeled AR9.6 in mice bearing ovarian and pancreatic cancer xenografts confirmed the MUC16-dependent tumor targeting by the radioimmunoconjugate. Radioactivity uptake was also observed in the distant lymph nodes (LNs) of mice bearing xenografts with high levels of MUC16 expression (i.e., OVCAR3 and Capan-2). IHC analyses of these PET-positive LNs highlighted the presence of shed antigen as well as necrotic, phagocytized, and actively infiltrating neoplastic cells. The humanization of AR9.6 did not compromise its ability to target MUC16-expressing tumors.Conclusions:The unique therapeutic mechanism of AR9.6 combined with its excellent in vivo tumor targeting makes it a highly promising theranostic agent. huAR9.6 is poised for clinical translation to impact the management of metastatic ovarian and pancreatic cancers.

31 March 2023
Verified
Other
Open access
SSSai Kiran Sharma
Sai Kiran Sharma
KMKyeara N. Mack
Kyeara N. Mack
APAlessandra Piersigilli
Alessandra Piersigilli
JPJacob Pourat
Jacob Pourat
KEKimberly J. Edwards
Kimberly J. Edwards
BZBrian Zeglis
Brian Zeglis
Supplementary Figure from ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody

31 March 2023
Verified
Other
Open access
SSSai Kiran Sharma
Sai Kiran Sharma
KMKyeara N. Mack
Kyeara N. Mack
APAlessandra Piersigilli
Alessandra Piersigilli
JPJacob Pourat
Jacob Pourat
KEKimberly J. Edwards
Kimberly J. Edwards
BZBrian Zeglis
Brian Zeglis
Supplementary Figure from ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody